Aptose Biosciences Inc. (APS.TO)
| Previous close | 1.6900 |
| Open | 1.7300 |
| Bid | 1.6900 x N/A |
| Ask | 1.7200 x N/A |
| Day's range | 1.6800 - 1.7300 |
| 52-week range | 1.5900 - 10.3500 |
| Volume | |
| Avg. volume | 9,398 |
| Market cap | 27.304M |
| Beta (5Y monthly) | 1.47 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -10.4100 |
| Earnings date | 14 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 31.02 |
GlobeNewswireAptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024
SAN DIEGO and TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, will report financial results for the first quarter ended March 31, 2024, on Tuesday, May 14, 2024, after the close of the market, and provide a corporate update. In addition, Rafael Bejar, MD, PhD, the Company’s Chief Medical Officer and resident Key Opinion
ZacksWhat Makes Aptose Biosciences (APTO) a New Buy Stock
Aptose Biosciences (APTO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Insider MonkeyAptose Biosciences Inc. (NASDAQ:APTO) Q4 2023 Earnings Call Transcript
Aptose Biosciences Inc. (NASDAQ:APTO) Q4 2023 Earnings Call Transcript March 26, 2024 Aptose Biosciences Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon. My name is Jonathan and I will be your conference operator today. I would like […]
